RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Contineum Therapeutics (NASDAQ:CTNM) and raises the price target from $30 to $32.
August 14, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Contineum Therapeutics and raises the price target from $30 to $32.
The raised price target and maintained Outperform rating from a reputable analyst at RBC Capital is likely to positively influence investor sentiment and drive short-term price appreciation for CTNM.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100